ImmunoPET Predicts Response to Met-targeted Radioligand Therapy in Models of Pancreatic Cancer Resistant to Met Kinase Inhibitors

Background: Pancreatic ductal adenocarcinoma (PDAC) has limited standard of care therapeutic options. While initially received with enthusiasm, results from targeted therapy with small molecule tyrosine kinases inhibitors (TKIs) have been mixed, in part due to poor patient selection and compensatory...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:Theranostics
Main Authors: Escorcia, Freddy E., Houghton, Jacob L., Abdel-Atti, Dalya, Pereira, Patricia R., Cho, Andrew, Gutsche, Nicholas T., Baidoo, Kwamena E., Lewis, Jason S.
Format: Artigo
Jezik:Inglês
Izdano: Ivyspring International Publisher 2020
Teme:
Research Paper
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC6929627/
https://ncbi.nlm.nih.gov/pubmed/31903112
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.7150/thno.37098
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki